ArticleMetabolites2021
Metabolomics Diagnosis of COVID-19 from Exhaled Breath Condensate.
Article in Metabolites, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 37 citations in OpenAlex.
- Higher 25(OH)D Levels at Admission Predict a Favorable Disease Evolution in Moderate-to-Severe COVID-19 Patients.International journal of molecular sciences · 2026Observational
- Molecular profiling of exhaled breath condensate in respiratory diseases.Annals of medicine · 2025Review
- Tile-Based Fisher Ratio Analysis with Support Vector Machine Regression Modeling of GC×GC-TOFMS Data of VOCs Produced byAnalytical chemistry · 2025Article
- A Review on Long COVID Screening: Challenges and Perspectives Focusing on Exhaled Breath Gas Sensing.ACS sensors · 2025Review
- Exhaled Breath Analysis: From Laboratory Test to Wearable Sensing.IEEE reviews in biomedical engineering · 2025Review
- Multiplatform Metabolomics: Enhancing the Severity Risk Prognosis of SARS-CoV-2 Infection.ACS omega · 2024Article
- Metabolic signatures of acute respiratory distress syndrome: COVID versus non-COVID.American journal of physiology. Lung cellular and molecular physiology · 2024Review
- COVID-19 and Comorbidities: What Has Been Unveiled by Metabolomics?Metabolites · 2024Review
- Breath metabolomics for diagnosis of acute respiratory distress syndrome.Critical care (London, England) · 2024Observational
- Comparing plasma and skin imprint metabolic profiles in COVID-19 diagnosis and severity assessment.Journal of molecular medicine (Berlin, Germany) · 2024Article
- Oxylipin concentration shift in exhaled breath condensate (EBC) of SARS-CoV-2 infected patients.Journal of breath research · 2023Article
- Exhaled breath condensate identifies metabolic dysregulation in patients with radiation-induced lung injury.American journal of physiology. Lung cellular and molecular physiology · 2023Article
- Comprehensive Two-Dimensional Gas Chromatography as a Bioanalytical Platform for Drug Discovery and Analysis.Pharmaceutics · 2023Review
- Diagnostic, Prognostic and Mechanistic Biomarkers of COVID-19 Identified by Mass Spectrometric Metabolomics.Metabolites · 2023Review
- Label-Free SERS for Rapid Differentiation of SARS-CoV-2-Induced Serum Metabolic Profiles in Non-Hospitalized Adults.Analytical chemistry · 2023Article
- Circulating Peptidome Is Strongly Altered in COVID-19 Patients.International journal of environmental research and public health · 2023Article
- Metabolomics as a powerful tool for diagnostic, pronostic and drug intervention analysis in COVID-19.Frontiers in molecular biosciences · 2023Review
- A comparative NMR-based metabolomics study of lung parenchyma of severe COVID-19 patients.Frontiers in molecular biosciences · 2023Article
- Breath Biomarkers of Influenza Infection.Open forum infectious diseases · 2022Article
- Potential Use of Exhaled Breath Condensate for Diagnosis of SARS-CoV-2 Infections: A Systematic Review and Meta-Analysis.Diagnostics (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 1 institution in 1 country.
Funding
Abstract
Infection from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can lead to severe respiratory tract damage and acute lung injury. Therefore, it is crucial to study breath-associated biofluids not only to investigate the breath's biochemical changes caused by SARS-CoV-2 infection, but also to discover potential biomarkers for the development of new diagnostic tools. In the present study, we performed an untargeted metabolomics approach using a bidimensional gas chromatography mass spectrometer (GCxGC-TOFMS) on exhaled breath condensate (EBC) from COVID-19 patients and negative healthy subjects to identify new potential biomarkers for the noninvasive diagnosis and monitoring of the COVID-19 disease. The EBC analysis was further performed in patients with acute or acute-on-chronic cardiopulmonary edema (CPE) to assess the reliability of the identified biomarkers. Our findings demonstrated that an abundance of EBC fatty acids can be used to discriminate COVID-19 patients and that they may have a protective effect, thus suggesting their potential use as a preventive strategy against the infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.